Mirum's revenue has grown rapidly, reaching $185.7M in 2026Q3 with a 39.6% year-over-year increase, while gross margins have held steady in the 81% to 83% range, suggesting durable unit economics.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue reached $185.7M in 2026Q3, up 39.6% year over year and decelerating from a 107.7% peak in 2024Q2, while gross margin held near 81% yet operating margin stayed negative at -32.2%, with a one-time $790.2M net loss in 2026Q1 warranting further investigation.
Mirum Pharmaceuticals and Incyte announced pivotal late-breaking results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva, accepted for presentation at ENDO 2026.
MarketBeat provides the latest MIRM stock analysis, price targets, earnings estimates, and headlines, indicating ongoing investor interest and potential upside.
Mirum maintains active investor relations with accessible contacts and stock quote information, suggesting transparency and engagement with shareholders.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$0.87-78.7% vs -$0.49 | $186M+4.3% vs $178M |
Q3 2026 Aug 5, 2026 | -$1.06-42.8% vs -$0.74 | $176M+5.9% vs $166M |
Q2 2026 May 6, 2026 | -$13.43-3257.5% vs -$0.40 | $160M+7.9% vs $148M |
Q1 2026 Feb 25, 2026 | -$0.11-650.0% vs $0.02 | $149M+4.5% vs $143M |
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.
Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.
While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Benchmark MIRM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mirum Pharmaceuticals, Inc. (MIRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $93.72 | $5.72B | -6.85 | 54.74% | -134.75% | -734% | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — |
Mirum Pharmaceuticals, Inc. (MIRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mirum Pharmaceuticals, Inc. (MIRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Oct 26, 2026·SEC
Oct 13, 2026·SEC
Get notified when MIRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mirum Pharmaceuticals, Inc. (MIRM) stock FAQ — growth, dividends, profitability & financials explained
Mirum Pharmaceuticals, Inc. (MIRM) reported $670.8M in revenue over the trailing twelve months. Revenue was $521.3M in fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 42.2% over the trailing twelve months, compared with the twelve months before.
No. Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $903.9M over the trailing twelve months.
Mirum Pharmaceuticals, Inc. (MIRM) had a return on equity (ROE) of -734.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Mirum Pharmaceuticals, Inc. (MIRM) had negative free cash flow of $503.3M over the trailing twelve months.
